An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo

Cancer Research

Volumn 58, Issue 21, 1998, Pages 4761-4765

  Kataoka, Masafumi ^a   Schumacher, Guido ^a   Cristiano, Richard J ^a   Atkinson, E Neely ^b   Roth, Jack A ^a,b   Mukhopadhyay, Tapas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; EPIESTRIOL; ESTRADIOL DERIVATIVE; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRANSGENE; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ESTRADIOL; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032211342     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Vogelstein, B., and Kinzler, K. W. p53 functions and dysfunction. Cell, 70: 523-526, 1992.
2. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
3. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
4. Yonish-Rouach, E., Deguin, V., Zaitchouk, T., Breugnot, C., Mishal, Z., Jenkins, J. R., and May, E. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene, 12: 2197-2205, 1996.
5. Johnson, P., Gray, D., Mowat, M., and Benchimol, S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol. Cell. Biol., 11: 1-11, 1991.
6. Chen, X. B., Ko, L. J., Jayaraman, L., and Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev., 10: 2438-2451, 1996.
7. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
8. Mukhopadhyay, T., and Roth, J. A. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene, 14: 379-384, 1997.
9. Mukhopadhyay, T., and Roth, J. A. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene, 17: 241-246, 1998.
10. Zhang, W. W., Fang, X., Mazur, W., French, B. A., Georges, R. N., and Roth, J. A. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther., 1: 5-13, 1994.
11. Hamada, K., Alemany, R., Zhang, W., Hittelman, W. N., Lotan, R., Roth, J. A., and Mitchell, M. F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res., 56: 3047-3054, 1996.
12. Clayman, G. L., El-Naggar, A. K., Roth, J. A., Zhang, W. W., Goepfert, H., Taylor, D. L., and Liu, T-J. In vivo molecular therapy with p53 adenovirus for microscopic-residual head and neck squamous carcinoma. Cancer Res., 55: 1-6, 1995.
13. Fotis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., and Schwelgerer, L. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature (Lond.), 368: 237-239, 1994.
14. Nishizaki, M., Fujiwara, T., Kagawa, S., Ogawa, N., Hizuta, N., Roth, J. A., and Tanaka, N. Antiangiogenic therapy for human lung cancer by wild-type p53-mediated down-regulation of vascular endothelial growth factor (VEGF) expression. Proc. Am. Assoc. Cancer Res., 38: 175, 1997.
15. Munshi, A., Ramesh, R., Marrogi, A., and Freeman, S. Evaluation of adenovirus p53 mediated bystander effect in vivo. Proc. Am. Assoc. Cancer Res., 38: 343, 1997.
16. Couffinhal, T., Kearney, M., Sullivan, A., Silver, M., Tsurumi, Y., and Isner, J. M. Histochemical staining following LacZ gene transfer underestimates transfection efficiency. Human Gene Ther., 8: 929-934, 1997.
17. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
18. Tishler, R. B., Lamppu, D. M., Park, S., and Price, B. D. Microtubule-active drugs Taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res., 55: 6021-6025, 1995.
19. Attalla, H., Makela, T. P., Adlercreutz, H., and Anderson, L. C. 2-methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem. Biophys. Res. Commun., 228: 467-473, 1996.
20. Maxwell, S. A., Roth, J. A., and Mukhopadhyay, T. Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung cells undergoing apoptosis. Electrophoresis, 17: 1772-1775, 1996.
21. Bouvet, M., Fang, B., Ekmekcioglu, S., Ji, L., Bucana, C. D., Hamada, K., Grimm, E. A., and Roth, J. A. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther., 5: 189-195, 1998.
22. Fang, B., Eisensmith, R. C., Wang, H., Kay, M. A., Cross, R. E., Landen, C. N., Gordon, G., Bellinger, D. A., Read, M. S., Hu, P. C., Brinkhous, K. M., and Woo, S. L. C. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum. Gene Ther., 6: 1039-1044, 1995.
23. Yang, Y., Greenough, K., and Wilson, J. M. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther., 3: 412-420, 1996.
24. Yang, Y., Trinchieri, G., and Wilson, J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med., 1: 890-893, 1995.
25. Fang, B., Koch, P. E., and Roth, J. A. Diminishing adenovirus gene expression and viral replication by promoter replacement. J. Virol., 71: 4798-4803, 1997.
26. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
27. Takahashi, Y., Bucana, C. D., Liu, W., Yoneda, Y., Kitadai, Y., Cleary, K. R., and Ellis, L. M. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J. Natl. Cancer Inst., 88: 1146-1151, 1996.